BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Merck KGaA readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Merck KGaA's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07170644-3189@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT07170644)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: A Study of Nir
 ogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (
 DT/AF)\nEstimated primary completion: 28 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07170644
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496048-2601@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06496048)
DESCRIPTION:Lurbinectedin\, phase 3\, Small Cell Lung Cancer.\nStudy: Lurbi
 nectedin or in Combination with Irinotecan Versus Topotecan in Patients wi
 th Relapsed SCLC\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06496048
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734066-2601@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Lurbinectedin: Phase 1/2 readout est. (NCT05734066)
DESCRIPTION:Lurbinectedin\, phase 1/2.\nStudy: Study of Lurbinectedin Monot
 herapy in Pediatric and Young Adult Participants With Relapsed/Refractory 
 Ewing Sarcoma\nEstimated primary completion: 28 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05734066
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814417-1965@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07814417)
DESCRIPTION:Cetuximab\, phase 2.\nStudy: A Study of Olomorasib (LY3537982) 
 in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation\n
 Estimated primary completion: November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07814417
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-2601@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Lurbinectedin: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Lurbinectedin\, phase 2\, Small Cell Lung Cancer.\nStudy: A Stu
 dy of Lurbinectedin in Combination With Durvalumab for the Treatment of Pa
 rticipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lurbinectedin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088290-2601@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Lurbinectedin: Phase 3 readout est. (NCT06088290)
DESCRIPTION:Lurbinectedin\, phase 3.\nStudy: Study of Lurbinectedin in Comb
 ination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment 
 in Participants With Metastatic Leiomyosarcoma (SaLuDo)\nEstimated primary
  completion: 30 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lurbinectedin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06088290
URL:https://assetmemo.bio/drug/lurbinectedin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
